Search results for: Health Data and Statistics
Filter search results
Adrian Towse
6 February 2014
…for health care payers and the pharmaceutical industry; and economic issues that affect both R&D for and access to treatments for diseases prevalent in the low and middle income countries….
Diseases of the Prostate
1 September 1995
…of Treatment; Incidence and Prevalence; Aetiology; Diagnosis; and Treatment. The feasibility of screening, and the cost to the NHS of prostatic diseases, are then discussed in Chapters five and six…
Hania El Banhawi
28 February 2023
…tobacco control policy in low- and middle- income countries and the EU, female genital mutilation across Africa and adolescent sexual and reproductive health in Egypt. Her masters thesis explored the…
Using Performance Thresholds to Affect GP Behaviour: Evidence from Scotland
4 March 2014
Whether and how a change in performance-related payment motivated change in GP behaviour in Scotland is investigated in a recent article by OHE’s Yan Feng and colleagues, Ada Ma (Hong…
Efficiency and Labour Productivity of Primary Care in England
23 April 2024, 2:00pm
The Office of Health Economics (OHE) has conducted a multi-year research programme funded by the Health Foundation on the efficiency of general practices in England and the determinants of labour…
Lavni Varyani
19 September 2025
…Group (now IQVIA), specializing in market access, pricing pathways, tendering and procurement processes, and commercial effectiveness. Her expertise includes the Saudi HTA system and spans diagnostics and high-value innovations across…
Brittany Darrow
2 October 2024
…particularly interested in rare diseases and the impact of pricing and payment models on innovation and health system sustainability. She is a member of OHE’s economics of innovation (EoI) theme. …
Sian Hodgson
27 September 2021
…research has focused on demonstrating the broader value of vaccines and exploring innovative funding mechanisms for preventative healthcare. Sian’s experience spans a variety of topics and includes both quantitative and…
Brand Names in Prescribing
1 September 1976
To present a balanced view of the brand name/generic controversy and the associated field of bioavailability. Many have discussed these problems; scientists, politicians, industrialists, legislators, hospital pharmacists, physicians, and clinical…